Lisata Therapeutics, Inc.
LSTA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.18 | 0.01 | -0.01 | 0.29 |
| FCF Yield | -77.98% | -90.89% | -163.71% | -48.00% |
| EV / EBITDA | -0.39 | 0.01 | 0.33 | -0.78 |
| Quality | ||||
| ROIC | -72.98% | -47.73% | -82.20% | -29.63% |
| Gross Margin | 100.00% | 0.00% | 52.54% | 0.00% |
| Cash Conversion Ratio | 0.97 | 0.96 | 0.39 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 3.37% | 6.63% | 3.81% | -152.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.72 | 0.87 | 0.56 | 0.83 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,364.95 | -4,675.48 | -14,044.57 | -12,834.73 |